150 related articles for article (PubMed ID: 29429988)
21. USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
Lim KS; Li H; Roberts EA; Gaudiano EF; Clairmont C; Sambel LA; Ponnienselvan K; Liu JC; Yang C; Kozono D; Parmar K; Yusufzai T; Zheng N; D'Andrea AD
Mol Cell; 2018 Dec; 72(6):925-941.e4. PubMed ID: 30576655
[TBL] [Abstract][Full Text] [Related]
22. USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis.
Ma A; Tang M; Zhang L; Wang B; Yang Z; Liu Y; Xu G; Wu L; Jing T; Xu X; Yang S; Liu Y
Oncogene; 2019 Mar; 38(13):2405-2419. PubMed ID: 30531833
[TBL] [Abstract][Full Text] [Related]
23. USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy.
Raimondi M; Cesselli D; Di Loreto C; La Marra F; Schneider C; Demarchi F
Autophagy; 2019 Apr; 15(4):613-630. PubMed ID: 30335599
[TBL] [Abstract][Full Text] [Related]
24. The structure of the deubiquitinase USP15 reveals a misaligned catalytic triad and an open ubiquitin-binding channel.
Ward SJ; Gratton HE; Indrayudha P; Michavila C; Mukhopadhyay R; Maurer SK; Caulton SG; Emsley J; Dreveny I
J Biol Chem; 2018 Nov; 293(45):17362-17374. PubMed ID: 30228188
[TBL] [Abstract][Full Text] [Related]
25. Active site alanine mutations convert deubiquitinases into high-affinity ubiquitin-binding proteins.
Morrow ME; Morgan MT; Clerici M; Growkova K; Yan M; Komander D; Sixma TK; Simicek M; Wolberger C
EMBO Rep; 2018 Oct; 19(10):. PubMed ID: 30150323
[TBL] [Abstract][Full Text] [Related]
26. TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis.
Niederkorn M; Hueneman K; Choi K; Varney ME; Romano L; Pujato MA; Greis KD; Inoue JI; Meetei R; Starczynowski DT
Cell Rep; 2020 Feb; 30(8):2776-2790.e6. PubMed ID: 32101751
[TBL] [Abstract][Full Text] [Related]
27. The Multifaceted Roles of USP15 in Signal Transduction.
Das T; Song EJ; Kim EE
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946990
[TBL] [Abstract][Full Text] [Related]
28. Loss of Xanthine Oxidoreductase Potentiates Propagation of Hepatocellular Carcinoma Stem Cells.
Sun Q; Zhang Z; Lu Y; Liu Q; Xu X; Xu J; Liu Y; Yu H; Yu D; Sun B
Hepatology; 2020 Jun; 71(6):2033-2049. PubMed ID: 31578733
[TBL] [Abstract][Full Text] [Related]
29. USP15: a review of its implication in immune and inflammatory processes and tumor progression.
Georges A; Gros P; Fodil N
Genes Immun; 2021 May; 22(1):12-23. PubMed ID: 33824497
[TBL] [Abstract][Full Text] [Related]
30. USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-κBp65.
Zhou L; Jiang H; Du J; Li L; Li R; Lu J; Fu W; Hou J
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459344
[TBL] [Abstract][Full Text] [Related]
31. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
[TBL] [Abstract][Full Text] [Related]
32. USP15 potentiates NF-κB activation by differentially stabilizing TAB2 and TAB3.
Zhou Q; Cheng C; Wei Y; Yang J; Zhou W; Song Q; Ke M; Yan W; Zheng L; Zhang Y; Huang K
FEBS J; 2020 Aug; 287(15):3165-3183. PubMed ID: 31903660
[TBL] [Abstract][Full Text] [Related]
33. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia.
Niederkorn M; Ishikawa C; M Hueneman K; Bartram J; Stepanchick E; R Bennett J; E Culver-Cochran A; Bolanos LC; Uible E; Choi K; Wunderlich M; Perentesis JP; M Chlon T; Filippi MD; Starczynowski DT
Leukemia; 2022 Feb; 36(2):438-451. PubMed ID: 34465865
[TBL] [Abstract][Full Text] [Related]
34. A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Nakaoku T; Kohno T; Araki M; Niho S; Chauhan R; Knowles PP; Tsuchihara K; Matsumoto S; Shimada Y; Mimaki S; Ishii G; Ichikawa H; Nagatoishi S; Tsumoto K; Okuno Y; Yoh K; McDonald NQ; Goto K
Nat Commun; 2018 Feb; 9(1):625. PubMed ID: 29434222
[TBL] [Abstract][Full Text] [Related]
35. Deubiquitylating Enzymes in Cancer and Immunity.
Ren J; Yu P; Liu S; Li R; Niu X; Chen Y; Zhang Z; Zhou F; Zhang L
Adv Sci (Weinh); 2023 Dec; 10(36):e2303807. PubMed ID: 37888853
[TBL] [Abstract][Full Text] [Related]
36. Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role.
Kannampuzha S; Gopalakrishnan AV
Med Oncol; 2023 Aug; 40(9):264. PubMed ID: 37550533
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
38. O-GlcNAcylation promotes topoisomerase IIα catalytic activity in breast cancer chemoresistance.
Liu Y; Yu K; Zhang K; Niu M; Chen Q; Liu Y; Wang L; Zhang N; Li W; Zhong X; Li G; Wu S; Zhang J; Liu Y
EMBO Rep; 2023 Jul; 24(7):e56458. PubMed ID: 37249035
[TBL] [Abstract][Full Text] [Related]
39. BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.
Barnett SE; Kenyani J; Tripari M; Butt Z; Grosman R; Querques F; Shaw L; Silva LC; Goate Z; Marciniak SJ; Rassl DM; Jackson R; Lian LY; Szlosarek PW; Sacco JJ; Coulson JM
Mol Cancer Res; 2023 May; 21(5):411-427. PubMed ID: 36669126
[TBL] [Abstract][Full Text] [Related]
40. The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation.
Barnett SE; Herrmann A; Shaw L; Gash EN; Poptani H; Sacco JJ; Coulson JM
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
